In development“In April 2026, we initiated an open-label Phase 2a clinical trial to evaluate the safety and tolerability of agazisiran in up to 24 participants with PNH and residual anemia.”
Sells it 12%, $4.5B a year“Nplate was launched in 2008 and is indicated to treat thrombocytopenia in patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.”
Latest 10-KFY2025Impairment / charge ·
Repatha and TEZSPIRE growth outweighed ENBREL’s price-led decline; Prolia and XGEVA biosimilars threaten faster erosion.
Revenue$36.8BYoY +10.0%
Net income$7.7BYoY +88.5%
Latest 10-QQ3 FY2026 ·
Repatha, UPLIZNA and IMDELLTRA demand more than offsets biosimilar erosion in Prolia and XGEVA.
Revenue$10.4BYoY +8.5%
Net income$3.9BYoY +20.1%
Latest 8-KPositiveEarningsGuidance raised ·
Repatha and IMDELLTRA sales surge as biosimilars hit Prolia and XGEVA; FY2026 revenue outlook rises to $38.9B–$39.7B.
Latest 8-KLeadership change ·
Former Yum! Brands CEO David Gibbs joins the board, bringing direct customer relationship experience to inform future product launches
Latest 8-KCybersecurity incident ·
Third-party cloud data theft deemed material due to file volume and potential sensitivity, including proprietary and patient health information
Latest 8-KShareholder vote ·
Shareholders rejected a requirement for an independent board chairman and elected all director nominees.
Latest 8-KCEO/CFO change ·
Thomas Dittrich returns from Galderma to succeed retiring CFO Peter Griffith, who stays through January 2027 to support the transition.
Latest 8-KDebt financing ·
Issues senior unsecured notes across four tranches, with maturities extending to 2056.
In development“Our second clinical-stage product candidate, BH-30236, is a CLK inhibitor currently being evaluated in an ongoing Phase 1 clinical trial in patients with R/R AML and HR-MDS.”
Sells it 21%, $10.3B a year“Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma.”
Latest 10-KFY2025MixedImpairment / charge ·
Reblozyl, Breyanzi and Camzyos gains offset Revlimid erosion; lower acquisition charges drove the GAAP earnings rebound.
Revenue$48.2BYoY −0.2%
Net income$7.1Bvs −$8.9B year ago
Latest 10-QQ3 FY2026MixedImpairment / charge ·
Eliquis drove growth as generics eroded Revlimid and Pomalyst; pipeline licensing charges weighed on earnings.
In development“Our third program, CITY-TFR2, is a City-engineered GalNAc-conjugated siRNA therapeutic in development for anemia of chronic disease, which accounts for up to 40% of all anemias and affects more than five million people in the United States.”
Supplies it“In our collaboration with Sanofi, we apply our XE technology to develop in vivo CRISPR-based therapies for sickle cell disease and other genetic diseases.”